Kailera Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 26, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 26, 2026
KLRA$14.24+3.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(amounts in thousands, except share data) (unaudited)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $111,826 | $160,267 |
| Marketable securities | 407,348 | 385,789 |
| Prepaid expenses and other current assets | 11,141 | 11,481 |
| Total current assets | 530,315 | 557,537 |
| Property and equipment, net | 1,854 | 1,955 |
| Restricted cash | 761 | 761 |
| Long-term marketable securities | 62,747 | 106,672 |
| Non-current clinical deposits | 13,318 | 12,185 |
| Operating lease right-of-use assets | 10,170 | 10,463 |
| Other non-current assets | 5,591 | 2,721 |
| Total assets | $624,756 | $692,294 |
| Liabilities, convertible preferred stock and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $7,095 | $7,529 |
| Accrued expenses and other current liabilities | 46,714 | 37,836 |
| Operating lease liabilities, current | 1,027 | 1,040 |
| Total current liabilities | 54,836 | 46,405 |
| Operating lease liabilities, non-current | 9,443 | 9,713 |
| Other non-current liabilities | 201 | 270 |
| Total liabilities | 64,480 | 56,388 |
| Commitments and contingencies (Note 12) | ||
| Convertible preferred stock: | ||
| Series A convertible preferred stock: $0.00001 par value; 35,677,603 shares authorized at March 31, 2026 and December 31, 2025; 35,677,603 shares issued and outstanding at March 31, 2026 and December 31, 2025; liquidation value of $356.8 million at March 31, 2026 | 390,306 | 390,306 |
| Series B convertible preferred stock: $0.00001 par value; 43,084,539 shares authorized at March 31, 2026 and December 31, 2025; 43,084,539 shares issued and outstanding at March 31, 2026 and December 31, 2025; liquidation value of $603.2 million at March 31, 2026 | 602,058 | 602,058 |
| Stockholders’ deficit: | ||
| Common stock, $0.00001 par value; 105,384,000 shares authorized at March 31, 2026 and December 31, 2025; 29,953 and 19,048 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 15,977 | 11,981 |
| Accumulated other comprehensive (loss) income | (532) | 229 |
| Accumulated deficit | (447,533) | (368,668) |
| Total stockholders’ deficit | (432,088) | (356,458) |
| Total liabilities, convertible preferred stock and stockholders’ deficit | $624,756 | $692,294 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.